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ABSTRACT 
 
Solid dispersions in water-soluble carriers 
have attracted considerable interest as a means of 
improving the dissolution rate, and hence possibly 
bioavailability, of a range of hydrophobic drugs. The 
aim of the present study was to improve the solubility 
and dissolution rate of a poorly water-soluble drug, 
nimodipine, by a solid dispersion technique. Solid 
dispersions were prepared by using polyethylene 
glycol 4000 (PEG- 4000) and polyvinylpyrrolidone 
K30 (PVPK30) in different drug-to-carrier ratios. The 
solid dispersions were prepared by melting method. 
Morphology of solid dispersions was characterised by 
scanning electron microscope. The pure drug, physical 
mixtures and solid dispersions were characterized by 
in vitro dissolution study. Dissolution characteristics 
were determined by using pH 4.5 acetate buffer 
containing 0.3% SDS. The very slow dissolution rate 
was observed for pure nimodipine and the dispersion 
of the drug in the polymers considerably enhanced the 
dissolution rate. This can be attributed to improved 
wettability and dispersibility, as well as decrease of 
the crystalline and increase of the amorphous fraction 
of the drug. Solid dispersions prepared with PEG-
4000 and PVPK30 showed the highest improvement in 
wettability and dissolution rate of nimodipine. Even 
physical mixtures of nimodipine prepared with both 
polymers also showed better dissolution profile than 
that of pure nimodipine. In conclusion, dissolution of 
nimodipine can be enhanced by the use of hydrophilic 
carriers PEG-4000 and PVPK30. 
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INTRODUCTION 
 
Nimodipine is a dihydropyridine calcium 
channel blocker. It has been shown to selectively 
regulate calcium channels to increase cerebral blood 
flow. Because of its high permeability, nimodipine 
can pass through the blood–brain barrier to protect 
brain cells by increasing their ability to tolerate 
hypoxia. The major therapeutic indication of 
nimodipine is for the prevention and treatment of 
delayed ischemic neurological disorders, which often 
occur in patients with subarachnoid hemorrhages [1]. 
Nimodipine has also been used in other 
cerebrovascular disorders, such as ischemic stroke and 
multi-infarct dementia [2,3]. 
Nimodipine is a poorly water-soluble drug 
and has a low bioavailability and limited clinical 
efficacy. For “low solubility/high permeability” drugs, 
dissolution plays an important role in their absorption 
[4]. Recently, for the purpose of improving oral 
bioavailability, a variety of techniques have been used 
to enhance the solubility in water and in biological 
fluids at physiological pH values, such as salt 
formation, solubilization, particle size reduction, solid 
dispersion , self-dispersing lipid formulations  and the 
use of inclusion compounds based on cyclodextrin [5]. 
Among these methods, solid dispersions is the most 
efficient. The use of solid dispersions to increase the 
dissolution rate and the bioavailability of poorly 
water-soluble drug is now well established [6,7,8]. An 
important influence on the properties of such solid 
dispersions is the method of preparation and the type 
of the carrier used [9,10,11,12]. The increase in 
dissolution rate from solid dispersions can be 
attributed to one or a combination of the following 
factors: a reduction of particle size of the drug, a 
solubilizing effect on the drug by the water soluble 
carrier, enhancement of the wettability and 
dispersibility of the drug by the carrier material, and 
the possible formation of a metastable dispersion that 
has a greater solubility resulting in a faster dissolution 
rate [13]. 
The popular carriers used in the formation 
of solid dispersions are polyethylene glycol (PEG) and 
polyvinylpyrrolidone (PVP) [14,15,16]. Both 
polymers are freely soluble in water and are available 
in various molecular weights. The molecular size of 
both polymers favors the formation of interstitial solid 
solutions [17]. Studies were carried out to enhance the 
dissolution of nimodipine using modified gum karaya, 
HPMC as carriers [18, 19]. The purpose of our study 
was to formulate the nimodipine solid dispersions 
using fusion method employing freely water-soluble 
carriers, PEG-4000 and PVPK30 and to evaluate the 
effect of the polymers on the dissolution rate of the 
drug. 
 
MATERIALS AND METHODS 
Materials:  
Nimodipine powder (Batch No. 200704004) 
was received as gift sample from China. PEG-4000 
(product of Germany) and PVPK30 (product of U.S.A) 
were supplied by Essen-Haus Sdn. Bhd., Malaysia. 
All other chemicals used are of analytical grade. 
Phase solubility studies:  
Phase and saturation solubility studies were 
performed according to the method described by 
Higuchi and Connors [20]. Pure nimodipine (50 mg) 
and a quantity of physical mixtures equivalent to 50 
mg of nimodipine prepared using PEG-4000 and 
PVPK30 were stirred vigorously in a water bath shaker 
at 37 ± 0.5o C in sealed vials with  25 ml of acetate 
buffer (pH 4.5) containing 0.3% sodium dodecyl 
sulfate for 24 h. The sample was then centrifuged and 
filtered through 0.45 μm membrane filter. After 
suitable dilution, the absorbance was measured at 236 
nm [21]. For the saturation solubility study, the same 
treatment was applied to solid dispersions and the 
concentration of nimodipine was determined. 
Preparation of physical mixtures in various drug 
and polymer ratios: 
Physical mixtures were prepared by 
homogeneous blending of previously sieved and 
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weighed nimodipine and polymer in ratio of 1:1 with a 
spatula in a mortar.  
Preparation of solid dispersions in various drug 
and polymer ratios: 
The solid dispersions of nimodipine and 
polymer were obtained by using drug and polymer in 
ratio of 1:1 by melting method.Nimodipine was added 
to the molten base comprising PEG-4000 or PVPK30. 
The blend was heated 10 oC above the melting point 
of each carrier for 5 min with continuous stirring. The 
systems were placed in a freezer at -20 oC for 24 h. 
The mass was crushed, ground gently with a mortar 
and pestle and passed through 500 µm sieve. The 
samples were kept in a desiccator until the next 
experiments.  
Scanning electron microscopy (SEM) analysis: 
Morphology of the solid dispersions was 
investigated using SEM study. The sample was 
individually glued on the brass sample holder with 
double-sided adhesive tape. The image was captured 
at an excitation voltage of 15kV from magnification 
100x and 500x. 
Determination of nimodipine content: 
An accurately weighed amount of each 
preparation was dissolved in small volume of 
methanol and further diluted with pH 4.5 acetate 
buffer containing 0.3% sodium dodecyl sulfate. The 
content of nimodipine was determined 
spectrophotometrically at 356 nm using UV 
spectrophotometer (Shimazu 1240, Japan). 
In vitro drug release study: 
Dissolution characteristics of nimodipine 
pure drug and different solid dispersions were studied 
in pH 4.5 acetate buffer containing 0.3% sodium 
dodecyl sulfate [21]. The drug, physical mixtures or 
solid dispersions (nimodipine and polymer in the ratio 
1:1) equivalent to 30 mg of NM were filled in empty 
hard gelatin capsules. The dissolution rate was carried 
out using USP XXI dissolution rate test apparatus with 
rotating basket in 900ml of dissolution medium. The 
stirring speed was 100 rpm and the temperature was 
maintained at 37°C ± 1°C. 5ml of aliquot of 
dissolution medium was withdrawn at time intervals 5, 
10, 15, 20, 30, 40, 50, 60, 80, 100 and 120 minutes by 
a syringe with Millipore filter with pore size of 0.45 
µg. The volume withdrawn at each time was replaced 
with dissolution medium (5 ml). The percentage of 
drug release was measured by UV spectrophotometer 
(Shimazu 1240, Japan) at λmax 356 nm. The 
dissolution experiments were conducted in triplicate. 
 
RESULTS AND DISCUSSION 
 
The complexation of nimodipine (NM) with 
PEG-4000 and PVPK30 was investigated using phase 
solubility studies. The phase-solubility diagram for the 
complex formation between nimodipine, PEG-4000 
and PVPK30 is presented in Fig 1. This plot shows that 
the aqueous solubility of the drug increases linearly as 
a function of PEG-4000 and PVPK30 concentrations. It 
is clearly observed that the solubility diagram of 
nimodipine in the presence of PEG-4000 and PVPK30 
can be classified as the AL type [20,22]. The linear 
host-guest correlation with slope of less than 1 
suggested the formation of a complex with respect to 
PEG-4000 and PVPK30 concentrations. The solubility 
of NM did not increase appreciably below 1% 
concentration of polymer. The increase in solubility 
was linear with respect to the weight fraction of the 
carrier above 1%. The increase in solubility of NM by 
PEG-4000 and PVPK30 may probably be due to the 
formation of soluble complexes between water-
soluble polymeric carrier and poorly soluble drug. The 
increase in NM solubility at 15% concentration of 
PEG-4000 and PVPK30 was seen to be approximately 
4.6- and 5.2-fold respectively after. 
 
The SEM of NM, NM:PEG-4000, 
NM:PVPK30 systems were shown in Fig 2. Pure drug 
scanning electron microscopic image showed 
crystalline drug of irregular shapes and sizes whereas 
in physical mixture, the PEG-4000 and PVPK30 existed 
as individual particles in which NM dispersed in its 
native crystalline form. In the solid dispersion 
products, the original morphology of the raw materials 
disappeared, and it was not possible to differentiate 
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the two components. The freeze-dried samples 
appeared as agglomerates. The drastic change of the 
particles’ shape and aspect in the freeze-dried samples 
was indicative of the presence of a new solid phase as 
opposed to the physical mixture, these particulates 
displayed much larger and rougher, presumably due to 
NM incorporated into the swelled polymer. 
The content of NM in each preparation was assayed 
by UV spectroscopy. The assay values were between 
96% and 99% of the theoretical values.  Dissolution 
profiles of are shown in Figure 3. Dissolution of solid 
dispersions (SDs) prepared using PEG-4000 and 
PVPK30 was more rapid and higher when compared to 
corresponding physical mixtures and pure drug. In the 
first 30 minutes, percent drug dissolved from NM pure 
drug was 2.4%, from physical mixtures was 19.9% 
(PEG-4000+NM) and 24.5% (PVPK30+NM). 
Significant increase (P<0.01) in dissolution rate of 
SDs prepared by melting method in weight ratio 1:1 
was observed. Percent drug dissolved in 30 minutes 
from PEG-4000+NM SDs was 88.2% and from 
PVPK30+NM was 91.4%. This was due to the effect of 
molecular dispersion of drug in PEG-4000 and 
PVPK30, the decreased crystallinity of NM existing in 
solid dispersions.  
 
It was reported that molecular dispersion is 
one of the important roles of drug release from the 
polymer-drug system. The present work shows that 
the dissolution rate of nimodipine from solid 
dispersions with PEG 4000 and PVPK30 improved to 
more than 80% compared to the pure drug. Further, 
solid dispersions performed better than the 
corresponding physical mixtures. Various studies have 
shown that freely water soluble carriers inhibits 
crystallization of drugs in solid dispersions resulting 
in amorphous form of the drug in the solid dispersions 
[17,23]. Crystallization inhibition is attributed to two 
effects: interactions, such as hydrogen bonding 
between the drug and the polymer and the entrapment 
of the drug molecules in the polymer matrix during 
solvent evaporation or a combination of both. The 
present study confirmed the advantage of improved 
aqueous solubility of NM in its solid dispersions form, 
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Fig 2. Scanning electron micrographs of (a) Nimodipine; (b) PEG - 4000 + Nimodipine physical mixture; (c) PVPK30 






Fig 3. Dissolution profile of (♦) NM, (■) PEG 4000 + NM physical mixture, (▲) PVPK30 + NM physical mixture, (●) 
PEG 4000 + NM solid dispersion and ( ) PVPK30 + NM solid dispersion in pH 4.5 acetate buffer containing 0.3% SDS. 
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